CDK4 and cancer: In addition, there were a few more selective inhibitors of the MEK1 pathway (cobimetinib), STAT3/MMPs (sanguinarine Cl), CDK4/6 (palbociclib isethionate) and two less characterized drugs with anti-infective (octenidine) and anti-bacterial/anti-fungal (zinc pyrithione) activities, the latter of which has recently been shown to have anti-cancer properties through a newly described proteasomal deubiquitinase inhibitor19.